SS
SNDX icon

SBI Securities’s Syndax Pharmaceuticals SNDX Stock Holding History

SBI Securities’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44 Hold
2
– – ﹤0.01% 3701
2026
Q1 		$47 Sell
2
-201
-99% -$4.37K ﹤0.01% 3590
2025
Q4 		$4.26K Buy
203
+1
+0.5% +$17 ﹤0.01% 2084
2025
Q3 		$3.11K Sell
202
-1
-0.5% -$13 ﹤0.01% 2247
2025
Q2 		$1.9K Buy
203
+2
+1% +$22 ﹤0.01% 2406
2025
Q1 		$2.47K Sell
201
-1,299
-87% -$18.3K ﹤0.01% 2202
2024
Q4 		$19.8K Buy
+1,500
New +$25.7K ﹤0.01% 1354

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

SBI Securities's SNDX Position: Q2 2026 in Review

SBI Securities held its Syndax Pharmaceuticals (SNDX) position steady in Q2 2026 at 2 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #3701.

SBI Securities first reported a position in SNDX in Q4 2024 and has held it in 7 quarters since. The position peaked at $19.8K in Q4 2024. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • SBI Securities held 2 shares of Syndax Pharmaceuticals worth $44 as of Q2 2026.
  • SBI Securities left its Syndax Pharmaceuticals share count unchanged in Q2 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3701 holding.
  • SBI Securities first reported a position in Syndax Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Syndax Pharmaceuticals position peaked at $19.8K in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.